IRONWOOD PHARMACEUTICALS, INC. Deferred Income Tax Assets, Net
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Deferred Income Tax Assets, Net of $69.06 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-08-06
- 2026-06-30: Deferred Income Tax Assets, Net $69.06M.
- 2026-03-31: Deferred Income Tax Assets, Net $84.24M.
- 2025-12-31: Deferred Income Tax Assets, Net $103.43M.
- 2025-09-30: Deferred Income Tax Assets, Net $101.69M.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2026-06-30 | $69.06M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $84.24M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $103.43M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $101.69M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $129.46M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $143.56M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $144.23M 10-K · filed 2026-02-26 |
| 2024-09-30 | $185.34M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $193.02M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $206.27M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $212.32M 10-K · filed 2025-03-31 |
| 2023-09-30 | $243.65M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $257.90M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $267.91M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $283.66M 10-K · filed 2024-02-16 |
| 2022-09-30 | $304.54M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $320.55M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $335.44M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $333.29M 10-K · filed 2025-03-31 |
| 2021-09-30 | $335.23M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $337.80M 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |